We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+0.49%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.58B
AUM Growth
-$476M
Cap. Flow
-$486M
Cap. Flow %
-30.8%
Top 10 Hldgs %
70.39%
Holding
38
New
4
Increased
7
Reduced
7
Closed
15

Top Buys

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$75.9M
2
HCA icon
HCA Healthcare
HCA
+$64.3M
3
EVHC
Envision Healthcare Holdings Inc
EVHC
+$61.3M
4
TSRO
TESARO, Inc.
TSRO
+$49.7M
5
RDUS
Radius Health, Inc.
RDUS
+$41.2M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$175M
2
GILD icon
Gilead Sciences
GILD
+$115M
3
AGN
Allergan plc
AGN
+$85.1M
4
SEM
Select Medical
SEM
+$76.8M
5
VTRS icon
Viatris
VTRS
+$52.5M

Sector Composition

Rank Sector Weight
1 Healthcare 61.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
$377M 23.88%
1,500,000
+500,000
+50% +$123M
NKTR icon
2
Nektar Therapeutics
NKTR
$2.41B
$125M 7.91%
346,667
-10,000
-3% -$3.13M
THC icon
3
Tenet Healthcare
THC
$21.8B
$94.5M 5.99%
5,750,000
+1,750,000
+44% +$29.7M
VTRS icon
4
Viatris
VTRS
$20.7B
$84.7M 5.37%
2,700,000
-1,545,889
-36% -$52.5M
PRGO icon
5
Perrigo
PRGO
$1.43B
$82.5M 5.23%
+975,000
New +$75.9M
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$78.9M 5%
2,458,100
– –
MYGN icon
7
Myriad Genetics
MYGN
$507M
$72.4M 4.59%
2,000,000
-1,000,000
-33% -$28.5M
EVHC
8
DELISTED
Envision Healthcare Holdings Inc
EVHC
$67.4M 4.27%
1,500,000
+1,150,000
+329% +$61.3M
OFIX icon
9
Orthofix Medical
OFIX
$477M
$65M 4.12%
1,375,000
-125,000
-8% -$5.89M
HCA icon
10
HCA Healthcare
HCA
$85.7B
$63.7M 4.04%
+800,000
New +$64.3M
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.64B
$63.5M 4.02%
1,400,000
+100,000
+8% +$4M
BKD icon
12
Brookdale Senior Living
BKD
$3.49B
$57.2M 3.63%
5,400,000
– –
BIVV
13
DELISTED
Bioverativ Inc. Common Stock
BIVV
$57.1M 3.62%
1,000,000
-174,300
-15% -$10.2M
TSRO
14
DELISTED
TESARO, Inc.
TSRO
$51.6M 3.27%
+400,000
New +$49.7M
AMAG
15
DELISTED
AMAG Pharmaceuticals
AMAG
$48.9M 3.1%
2,650,000
+950,000
+56% +$17.7M
RDUS
16
DELISTED
Radius Health, Inc.
RDUS
$44.3M 2.81%
1,150,000
+1,050,000
+1,050% +$41.2M
GILD icon
17
Gilead Sciences
GILD
$163B
$40.5M 2.57%
500,000
-1,500,000
-75% -$115M
ELGX
18
DELISTED
Endologix Inc
ELGX
$35.7M 2.26%
800,000
+50,000
+7% +$2.28M
NVTA
19
DELISTED
Invitae Corporation
NVTA
$22.5M 1.42%
2,398,123
– –
OPCH icon
20
Option Care Health
OPCH
$3.36B
$17.3M 1.1%
1,575,050
-969,950
-38% -$11M
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$16.5M 1.04%
+200,000
New +$15.9M
ATRA icon
22
Atara Biotherapeutics
ATRA
$73.6M
$8.86M 0.56%
21,420
– –
BIOL
23
DELISTED
Biolase, Inc.
BIOL
$3.21M 0.2%
427
– –
BIIB icon
24
Biogen
BIIB
$30.7B
– –
-100,000
Closed -$27.1M
GILD icon
25
CALL
Gilead Sciences
GILD
$163B
– –
-2,000,000
Closed -$142M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Camber Capital Management held 38 positions worth $1.58B, down 23% from $2.05B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Camber Capital Management withdrew a net $486M in Q3 2017, closing 15 positions and reducing 7 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $175M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 69% a quarter earlier.

Against the trend, Camber Capital Management opened a new position in Perrigo worth $82.5M.

  • Camber Capital Management's largest Q3 2017 buy was Perrigo: 975,000 shares worth $82.5M.
  • Camber Capital Management added most to Envision Healthcare Holdings Inc in Q3 2017, an estimated $61.3M increase.
  • Camber Capital Management's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $115M.
  • Camber Capital Management fully exited Teva Pharmaceuticals in Q3 2017, selling an estimated $175M.
  • Camber Capital Management's ten largest holdings make up 70% of its $1.58B portfolio in Q3 2017.
  • Camber Capital Management opened 4 new positions and closed 15 in Q3 2017.
  • Camber Capital Management's portfolio value fell 23% quarter-over-quarter to $1.58B.

Based on Camber Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.